Mallinckrodt: Data on Hepatorenal Syndrome Reversal at Critical Care Congress

 Findings from a retrospective analysis suggest that patients with baseline acute-on-chronic liver failure (ACLF) grade ≤2 treated with TERLIVAZ^® plus albumin had a higher incidence of HRS reversal than those treated with placebo plus albumin¹

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from a retrospective analysis of three North American-centric, Phase III, randomized, placebo-controlled studies comparing the incidence of hepatorenal syndrome (HRS) reversal with baseline acute-on-chronic liver failure (ACLF) grade in adults with rapid reduction in kidney function² treated with TERLIVAZ^® plus albumin versus those treated with placebo plus albumin. Investigators will present the findings during an oral presentation at the SCCM 2023 Critical Care Congress on January 22, taking place in San Francisco, CA from January 21-24.

https://www.biospace.com/article/releases/mallinckrodt-presents-new-terlivaz-terlipressin-for-injection-data-on-hepatorenal-syndrome-hrs-reversal-at-the-society-of-critical-care-medicine-sccm-2023-critical-care-congress/